Publications by authors named "Beth Arrowsmith"
Background: In Australian remote communities, First Nations children with otitis media (OM)-related hearing loss are disproportionately at risk of developmental delay and poor school performance, compared to those with normal hearing. Our objective was to compare OM-related hearing loss in children randomised to one of 2 pneumococcal conjugate vaccine (PCV) formulations.
Methods And Findings: In 2 sequential parallel, open-label, randomised controlled trials (the PREVIX trials), eligible infants were first allocated 1:1:1 at age 28 to 38 days to standard or mixed PCV schedules, then at age 12 months to PCV13 (13-valent pneumococcal conjugate vaccine, +P) or PHiD-CV10 (10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine, +S) (1:1).
Article Synopsis
- Australian First Nations children face high risks of bacterial infections like otitis media, prompting the PREVIX trials to assess the effectiveness of new pneumococcal vaccines.
- The PREVIX_BOOST trial involved Aboriginal children in remote Northern Territory communities, evaluating the immune response to either a PCV13 or PHiD-CV10 booster after earlier vaccine schedules.
- The study found that 95% of the 261 participants had adequate serum samples for analysis, aimed at measuring antibodies and overall health outcomes post-vaccination.
Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial.
BMC Pediatr
March 2021
Article Synopsis
- Aboriginal infants in remote Australian communities are at a high risk of otitis media, which can lead to hearing loss and social disadvantages, and the study compared vaccine effectiveness between Synflorix™ and Prevenar13™.* -
- In a trial involving 425 infants, outcomes were assessed at multiple time points (1, 2, 4, 6, and 7 months) to determine the prevalence and severity of otitis media, revealing no significant differences between the vaccine schedules.* -
- Results indicated a high prevalence of otitis media across all groups, with 71.4% of infants assessed showing conditions warranting specialist referral by 4, 6, and 7 months.*
Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial.
Vaccine X
April 2021
Background: Aboriginal children living in remote communities are at high risk of early and persistent otitis media. and non-typeable (NTHi) are primary pathogens. Vaccines with potential to prevent early OM have not been evaluated in this population.
View Article and Find Full Text PDF